GlassScriptPhysician profile
Upinder K Dhand
NPI 1558328906
$2,502.44
in general payments reported to CMS, 2019-2025
36 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $707 · 2021: $52.11 · 2022: $170 · 2023: $325 · 2024: $290 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $326.74 | 2019-2025 | |
| Allergan, INC. | $182.25 | 2019-2020 | |
| Abbvie INC. | $176.40 | 2019-2025 | Botox |
| Ucb, INC. | $149.12 | 2019-2023 | Briviact |
| Amgen INC. | $140.51 | 2019-2020 | |
| Genzyme Corporation | $126.74 | 2019-2020 | |
| Biogen, INC. | $125.17 | 2019-2024 | Skyclarys, Tysabri |
| Supernus Pharmaceuticals, INC. | $123.76 | 2019-2020 | |
| Viatris Specialty LLC | $123.35 | 2025 | Yupelri |
| Mdd US Operations, LLC | $89.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $81.77 | 2020 | |
| Lilly USA, LLC | $80.10 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $64.73 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $55.62 | 2019-2022 | |
| Csl Behring | $55.60 | 2019-2023 | Hizentra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.58 | 2024-2025 | Hyqvia |
| Emd Serono, INC. | $41.15 | 2022-2023 | Mavenclad |
| Catalyst Pharmaceuticals, INC. | $40.89 | 2022-2024 | |
| Akcea Therapeutics, INC. | $40.12 | 2019 | |
| Amneal Pharmaceuticals LLC | $38.24 | 2019-2020 | |
| Eisai INC. | $35.19 | 2020-2024 | |
| Neuropace, INC. | $32.83 | 2022 | |
| Tanabe Pharma America, INC. | $31.61 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $31.45 | 2019-2022 | |
| Neurelis, INC. | $29.78 | 2020-2021 | |
| Cycle Pharmaceuticals INC | $29.25 | 2025 | Tascenso Odt, Bafiertam |
| Argenx US, INC. | $25.05 | 2023 | |
| Tg Therapeutics, INC. | $24.80 | 2023 | |
| Ge Healthcare | $23.77 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $22.80 | 2023 | Dysport |
| Immedica Pharma US, INC. | $22.40 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $21.83 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.31 | 2023 | Rexulti |
| Grifols USA, LLC | $16.36 | 2024 | Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $15.83 | 2021 | |
| Merck Sharp & Dohme LLC | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upinder Dhand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.